We believe that our lead product candidate, APL-2, has the potential to be a first-in-class treatment targeting C3 that may address the limitations of existing treatment options or provide a treatment option where there currently is none. APL-2 has already shown activity that we believe is clinically meaningful in clinical trials for two distinct medical conditions—geographic atrophy in age-related macular degeneration (GA) and paroxysmal nocturnal hemoglobinuria (PNH). We plan to conduct additional clinical trials in GA, PNH, autoimmune hemolytic anemia (AIHA) and complement-dependent nephropathies.